A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

U Lassen; L R Molife; Janice Marie Sorensen; S-A Engelholm; L Vidal; R Sinha; R T Penson; P Buhl-Jensen; E Crowley; J Tjornelund; P Knoblauch; J S de Bono

doi:10.1038/sj.bjc.6605726

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

U Lassen, L R Molife, Janice Marie Sorensen, S-A Engelholm, L Vidal, R Sinha, R T Penson, P Buhl-Jensen, E Crowley, J Tjornelund, P Knoblauch, J S de Bono

84 Citationer (Scopus)

Abstract

This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

Originalsprog	Engelsk
Tidsskrift	British Journal of Cancer
Vol/bind	103
Udgave nummer	1
Sider (fra-til)	12-7
Antal sider	6
ISSN	0007-0920
DOI	https://doi.org/10.1038/sj.bjc.6605726
Status	Udgivet - 29 jun. 2010

Adgang til dokumentet

10.1038/sj.bjc.6605726

Citationsformater

Lassen, U., Molife, L. R., Sorensen, J. M., Engelholm, S.-A., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P., & de Bono, J. S. (2010). A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. British Journal of Cancer, 103(1), 12-7. https://doi.org/10.1038/sj.bjc.6605726

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. / Lassen, U; Molife, L R; Sorensen, Janice Marie et al.
I: British Journal of Cancer, Bind 103, Nr. 1, 29.06.2010, s. 12-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Lassen, U, Molife, LR, Sorensen, JM, Engelholm, S-A, Vidal, L, Sinha, R, Penson, RT, Buhl-Jensen, P, Crowley, E, Tjornelund, J, Knoblauch, P & de Bono, JS 2010, 'A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours', British Journal of Cancer, bind 103, nr. 1, s. 12-7. https://doi.org/10.1038/sj.bjc.6605726

@article{48c021854b3a4d45a32221086e7392bf,

title = "A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours",

abstract = "This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.",

author = "U Lassen and Molife, {L R} and Sorensen, {Janice Marie} and S-A Engelholm and L Vidal and R Sinha and Penson, {R T} and P Buhl-Jensen and E Crowley and J Tjornelund and P Knoblauch and {de Bono}, {J S}",

year = "2010",

month = jun,

day = "29",

doi = "10.1038/sj.bjc.6605726",

language = "English",

volume = "103",

pages = "12--7",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

AU - Lassen, U

AU - Molife, L R

AU - Sorensen, Janice Marie

AU - Engelholm, S-A

AU - Vidal, L

AU - Sinha, R

AU - Penson, R T

AU - Buhl-Jensen, P

AU - Crowley, E

AU - Tjornelund, J

AU - Knoblauch, P

AU - de Bono, J S

PY - 2010/6/29

Y1 - 2010/6/29

N2 - This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

AB - This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

U2 - 10.1038/sj.bjc.6605726

DO - 10.1038/sj.bjc.6605726

M3 - Journal article

C2 - 20588278

SN - 0007-0920

VL - 103

SP - 12

EP - 17

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater